3 Results for "

p-Tyr705

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "p-Tyr705" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-149007
CAS No.: 2503096-50-0
Purity:  98.30%
Target:  

STAT Apoptosis

Research Areas:  

Cancer

STAT3-IN-11 (7a) is a selective STAT3 inhibitor that inhibits the phosphorylation of STAT3 at site pTyr705. STAT3-IN-11 inhibits the phosphorylation of downstream genes (Survivin and Mcl-1) without affecting its upstream tyrosine kinases (Src and JAK2) levels and p-STAT1 expression. STAT3-IN-11 can induce cancer cell apoptosis, which is potential for the discovery of effective STAT3 inhibitors and antitumor agents against cancers .
loading...
    loading...
Cat. No.: HY-169797
CAS No.: 3033049-16-7
Target:  

STAT Survivin Apoptosis

Research Areas:  

Cancer

STAT3-IN-38 (Compound 4m) is an inhibitor of STAT3 (KD of rhSTAT3: 45.33  µM). STAT3-IN-38 binds to the SH2 domain of STAT3 protein and suppresses the STAT3’s phosphorylation at site pTyr705 as well as its downstream genes (Survivin and Mcl-1). STAT3-IN-38 could block cell-cycle and induce Apoptosis in colorectal cancer cells .
loading...
    loading...
Cat. No.: HY-189693
CAS No.: 459193-26-1
Research Areas:  

Cancer

c-Met/STAT3-IN-2 is a c-Met and STAT3 inhibitor with IC50 values of 0.20 μM and 0.74 μM, respectively. c-Met/STAT3-IN-2 inhibits c-Met and STAT3 phosphorylation, binds to the STAT3 SH2 domain, and blocks pTyr705 recognition. c-Met/STAT3-IN-2 induces cancer cell apoptosis (apoptosis) and G2/M phase arrest, upregulates P53, Bax, PUMA, caspases-3, -8, and -9, and downregulates Bcl-2. c-Met/STAT3-IN-2 has broad-spectrum anticancer activity, inhibits cancer cell proliferation, and exhibits lethal activity against various cancer cell lines. c-Met/STAT3-IN-2 shows minimal off-target inhibition of STK3, STK4, PI3Kdelta, and VEGFR3. c-Met/STAT3-IN-2 can be used for research related to colorectal cancer, leukemia, non-small cell lung cancer, and breast cancer cells .
loading...
    loading...